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Abstract: The treatment of diseases with honeybee venom (apitoxin) is a branch of apitherapy, which has yet to find substantial scientific
support. In this present study, we used apitoxin to investigate its effects on diabetes mellitus (DM) in rats. The use of apitoxin injection
on single-dose streptozotocin (STZ)-treated rat model was selected, and the study took 28 days. Fasting blood glucose (FBG) was
measured weekly. Biochemical and hematological parameters, oxidative stress markers, and insulin levels were measured from the
blood samples provided on the last day of the study, and the DNA damage marker (8-OHdG) was measured from urine samples.
We found that apitoxin increased malondialdehyde (MDA) and carbonylated protein (PCO), and decreased glutathione (GSH) levels
significantly. Additionally, apitoxin increased nitric oxide (NOx) levels significantly in diabetic rats. The findings suggest that apitoxin
increases oxidative stress to some extent. Apitoxin had no significant effect on plasma insulin levels. Apitoxin apparently caused small
decreases in FBG levels. Apitoxin appears to cause an increase in aspartate aminotransferase (AST), and an increase in the number of
platelets (PLT) and granulocytes (GRAN) in diabetic rats. Consequently, the possible antidiabetic effect of apitoxin on DM could only
be supported at the preliminary level and presented with speculation in this state of the study.
Key words: Apitherapy with apitoxin, honeybee venom, plasma insulin concentration, redox system, streptozotocin-induced diabetes
mellitus

1. Introduction
Diabetes mellitus (DM) is a series of metabolic disorders
that is common among endocrine system diseases [1].
Free radicals prevent the preservation of homeostasis in
the redox system of the organism, causing oxidative stress.
Thus, oxidative stress damages cellular structures and
functions, disrupting glucose, protein, and lipid structures.
These irregularities cause disorders in insulin secretion or
interaction [2,3]. This chain of oxidative events that trigger
each other prepares the ground for the development of
diabetic complications [2].
Nowadays, we use a variety of medications to treat
diabetes, but these are not always effective. Therefore, the
quest for alternative treatment methods is paramount at
this stage. However, scientific evidence for recognized
alternative treatment methods is either limited or absent
[4]. One of these alternative methods is apitherapy, and
there is some scientific research on therapy with honeybee
venom (apitoxin). Researchers have discovered that
apitoxin interferes with inflammatory processes. Bioactive
peptide components in apitoxin are responsible for this
effect of apitoxin [5].

Some studies have emphasized that apitoxin causes in
vitro insulin release [6] and the enhancement of in vivo
insulin release [7]. One study also finds that apitoxin
causes improvements in glucose metabolism and lipid
profile [8].
The present study thus has been designed with an
intention to assess the possible antidiabetic effects of
apitoxin in the rat DM model induced by streptozotocin
(STZ) and its effects on the redox system by supporting
it with some biochemical and hematological parameters,
which are all parameters related to diabetes.
2. Materials and methods
2.1. Animals
Three-month-old male Wistar Albino rats (200–320
g) were purchased from Afyon Kocatepe University
Experimental Animal Research and Application Center
(Afyonkarahisar, Turkey). All rats were acclimated 10 days
before the study and were housed up to four per cage in
polycarbonate cages and maintained in 12 h dark/light
cycles and 65% humidity at 20 ± 1°C. Rats were randomly
divided into four groups (n = 10 in each group). The
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experimental protocol was approved by the Animal Ethics
Committee of Afyon Kocatepe University (Ref. No: 44515). Animals had free access to water and food. Bodyweight
and fasting blood glucose (FBG) measurements of the
rats were measured at the same time (9 a.m.) on the day
of the initiation of experimental applications, and once
a week after starting the applications. Weekly water and
food intake parameters were recorded at the same time
(10 a.m.) of each day. On the last day of the study, animals
that were fasted for 12 h were anesthetized with 10 mg/kg
Xylazine HCl plus 50 mg/kg Ketamine HCl. All rats were
euthanized by exsanguination under anesthesia at the end
of the experiment.
2.2. Experimental protocol
DM was induced with an intraperitoneal (i.p.) injection
of STZ (50 mg/kg; Sigma–Aldrich Corp., St. Louis, MO,
USA) dissolved in citrate buffer at pH 4.5, as previously
described [9] in twenty animals. The FBG levels of the
rats, which were fasted 12 hours before, once a week, were
measured from the blood taken from the tail veins with
glucometer, and those with a blood glucose level above
200 mg/dL were considered diabetic [10]. After injection,
10% (w/v) sucrose water and food were provided for 24
h [9]. Lyophilized form of apitoxin (Catalog number:
V3375, Sigma–Aldrich Corp., St. Louis, MO, USA) was
dissolved in saline (154 mmol/L NaCl) at a dose of 0.5 mg/
kg, as previously described [8]. One of the nondiabetic
groups was used as control (n = 10, i.p. saline injection/
day; group C) and the other treated with apitoxin (n = 10,
i.p. apitoxin injection/day; group A); one of the diabetic
groups was treated with apitoxin (n = 10, i.p. apitoxin
injection/day; group DA) and the other with saline (n =
10, i.p. saline injection/day; group D) for 28 days. At the
end of the experiments, blood samples were obtained by
cardiac puncture for measurement of redox, biochemical,
and hematologic parameters. Urine samples were obtained
by cystocentesis for measurement of 8-hydroxy-2’Deoxyguanosine (8-OhdG) levels.
2.3. Measurement of some redox parameters
Blood malondialdehyde (MDA) levels were determined by
the colorimetric test, also known as the double warming
method, proposed by Draper and Hadley (1990), as
previously described. In principle, it is based on the
reaction of MDA with thiobarbituric acid (TBA) to give
absorbance at a certain wavelength [11]. Nitric oxide (NOx)
levels were determined from the blood by the colorimetric
assay, also known as Griess method. In principle, nitrate is
reduced to nitrite by vanadium chloride and is based on
the separation of nitrogen atoms of nitrite by sulfanilamide
in acidic medium and the formation of colored azocomplex with N-(1-Naphthyl)ethylenediamine [12]. Total
oxidant status (TOS) and Total antioxidant status (TAS)
were determined using colorimetric assay kits (Relassay
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Diagnostics LLC, Gaziantep, TR). TOS is a quantitative
test used to measure the total concentration of oxidant
substances in the blood, while TAS is a quantitative test
used to measure the total concentration of antioxidant
substances. Standard dilutions, sampling, and incubation
were performed following the instructions in the user
manual of the kits. Reduced glutathione (GSH) levels were
determined from the blood by the colorimetric assay, also
known as Ellman’s method. It is principally based on the
catalytic reaction of Ellman reagent (DTNB) with GSH
and GSSG [13].
2.4. Determination of PCO, Insulin, and 8-OHdG
Protein carbonyl (PCO) and insulin levels were assessed in
blood plasma, and 8-OHdG levels were assessed in urine
with colorimetric antigen-antibody reaction kits (Shanghai
Sunred Biological Technology Co., Ltd). The amount of
PCO, insulin, and 8-OHdG in the samples was determined
according to the color intensity resulting from the antigen
and antibody reaction. Blood samples were extracted for
10 min at 2500 rpm to obtain blood plasma. Extraction
was performed at + 4 °C in the Ortoalresa Digicen 21R
centrifuge. 1 mL plasma and 0.5-1 ml urine samples
were taken into 1.5 mL Eppendorf tubes and stored at
–80°C until required measurements were made. Standard
dilutions, sampling, and incubation were again performed
following the instructions in the user manual of the kits,
and reading of absorbance values was performed on Fisher
Scientific-accuSkan ELISA microplate reader.
2.5. Biochemical and hematologic parameters
Blood samples (5-8 mL) were taken into tubes with
K2EDTA. The biochemical profile was determined with an
autoanalyzer (Cobas Integra 400), and the hematological
profile was determined with a fully automated instrument
(Mindray BC-2800vet).
2.6. Statistical analysis
Data of the results are expressed as means ± S.D. The
normality test was performed with the Kolmogorov–
Smirnov test. Statistical differences among groups were
determined using ANOVA followed by Bonferroni
posthoc test. The data were evaluated with SPSS software
(SPSS v.20; Chicago, IL, USA). Differences were considered
significant at P < 0.05.
3. Results
3.1. Alterations in redox balance
The results showed that experimental DM led to lipid
peroxidation, leading to an increase in MDA. Bee
venom caused an increase in MDA in group A (Figure
1A). The levels of NOx increased significantly in the
DA group (Figure 1B). PCO levels have increased in all
groups compared with the control group (Figure 1C). No
significant effect of apitoxin alone on the levels of 8-OhdG
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was detected, although an increase in those of the D and
DA groups was observed (Figure 1D). The levels of TOS
were increased in the D and DA groups compared with
those of the C group, whereas the levels of TAS were
decreased (Figure 1E, 1F). The levels of GSH decreased
in all groups compared with those of the C group (Figure
1G).
3.2. Alterations in insulin levels
The levels of insulin decreased in group D compared
with group C. No significant effects of apitoxin alone
on the insulin levels were observed. There was a slight,
insignificant increase in insulin levels in the DA group
(Figure 1H).
3.3. Bee venom decreased FBG
All STZ-injected rats had developed hyperglycemia (200
mg/dl); FBG concentration of group D reached its highest
level (P < 0.05) in the 4th week compared with STZ
induction day. However, DA rats showed a significant
(P < 0.05) decrease in FBG in the first week of the study.
FBG concentration of the apitoxin-treated rats in group A
shows a significant decrease (P < 0.05) in the 2nd week
compared to day 0, and in the 2nd, 3rd, and 4th weeks
compared to STZ-injection day (Figure 2).
3.4. Alterations in biochemical parameters
We observed an increase in AST in group A. AST also
increased in diabetic rats. Alanine aminotransferase (ALT)
did not show a significant increase in group A; however, the
increase in D and DA groups is significant. Apitoxin caused
an insignificant increase in TC and low-density lipoprotein
cholesterol (LDL) in group A, while a significant increase
was observed in group D and DA. While no significant
change in very low-density lipoprotein cholesterol (VLDL)
was observed in the A and D group, a significant decrease
was observed in the DA group. The changes observed
in triglyceride and high-density lipoprotein cholesterol
(HDL) parameters are insignificant. It was observed that
VLDL decreased when rats of group DA and rats of both A
and D were compared (Table 1).
3.5. Alterations in hematologic parameters
No significant changes were observed in HCT, RBC, and
HGB levels. An increase in MCV and a decrease in MCHC
were observed in the DA group. The decrease in MCHC in
the DA group was significant. Leucocytes (WBC) in group
A did not show a significant change. The increase in WBC
in the D and DA groups was also significant. There was a
significant increase in lymphocyte (LYM) count in D and
DA. The count of GRAN increased in DA. Apitoxin caused
a decrease in monocyte (MON) percentage. DM caused
a decrease in MON percentage. It was observed that the
percentage of MON in the DA group approached that of
the C group. The effect of apitoxin to increase the number
of PLT has been observed. DM caused a decrease in the

number of PLT. MPV increased in the D and DA groups
(Table 2)
3.6. Changes in bodyweight, food, and water intake
Bodyweight changes of rats in groups C, A, D, and DA were
observed as gain, no change, loss between 0 and 4 weeks
and loss between 0 and 3 and 0 and 4 weeks during the
study time, respectively (P < 0.05). A graph showing the
change of bodyweight in the weekly time unit according
to the in-group comparison of the differences (Figure 3A)
is shown. We observed a decrease in food intake in the C
group in the 1st and 2nd weeks, and in the A group in the
1st, 2nd, 3rd, and 4th weeks. There was a gradual increase
in the food intake of D group. We did not observe in-group
statistical differences in the DA group at the 2nd, 3rd, and
4th weeks (P < 0.05), (Figure 3B).
We did not observe any change in water intake in group
C. We observed that in group A, water intake decreased
in the 3rd and 4th weeks compared to the initiation day
of the study and the 1st week. We observed that water
intake increased in D and DA groups. We observed that
in all weeks except week 2, water and food intake was
significantly lower in group DA than group D (P < 0.05),
(Figure 3C).
3.7. Behavioral and physical changes
Aggression, convulsion, swelling around the eyes, nose,
mouth, and neck and difficulty in breathing were observed
in rats treated with bee venom.
4. Discussion
As we have observed in our study, free radical production
in DM [3] increases the susceptibility to lipid peroxidation
[14,15]. In some studies, it was reported that blood MDA
levels decreased in diabetic rats due to the effect of apitoxin
[16]. Considering other studies, findings of elevated MDA
levels have been reported in in vitro human whole blood
samples, depending on the dose of apitoxin and the duration
of exposure [17]. Similar findings have been reported in
rabbit renal proximal tube cells [18], mouse serum [19],
and liver tissue [20]. Apitoxin may cause lipid peroxidation.
PLA2 may disrupt membrane integrity by hydrolyzing the
cell membrane [21], thus causing an increase in MDA.
The increase in NOx levels in diabetic rats with apitoxin
injection is probably due to oxidative stress [22].
The production of modified proteins in diabetic rats
with apitoxin injection increased, due to diabetic oxidative
stress and glucose accumulation, or the effects of both
[23]. In this study, apitoxin increased the production of
oxidants, causing an increase in PCO levels that triggered
uncompensated reactive oxygen species (ROS) production,
as previously described [24].
In diabetic cases, 8-OHdG excretion increased in
urine [25]. The increase in 8-OHdG in rats with DM was
consistent with reports from others.
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Figure 1. Redox parameters and insulin measurement graphs. Bar graphs showing the quantification, in various units and +S.D., of
malondialdehyde (MDA), nitric oxide (NOx), protein carbonyl (PCO), DNA damage marker (8-OHdG), total oxidant status (TOS), total
antioxidant status (TAS), reduced glutathione (GSH), and insulin parameters measured in study groups (ANOVA, posthoc Bonferroni
test, *P < 0.05; **P < 0.0001). C, control group; A, apitoxin treated group; D, diabetic group; DA, apitoxin treated diabetic group.
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Figure 2. Fasting blood glucose graphs. Bar graph showing the means, in mg/dl and +S.D., of FBG
in-group comparison parameters measured weekly in study groups (ANOVA, post-hoc Bonferroni
test, **P < 0.05, compared with day 0; ‡‡P<0.05, compared with STZ injection day). C, control group;
A, apitoxin treated group; D, diabetic group; DA, apitoxin treated diabetic group. 0, first day of FBG
measurement; STZ, FBG measurement of STZ injection day; 1, 2, 3, 4, weeks after STZ injection day.
Table 1. The means of biochemical parameters measured in groups.
C
(n = 10)

A
(n = 10)

D
(n = 10)

DA
(n = 10)

P

AST (U/L)

21.56 ± 4.93

170.18 ± 65.56

173.28 ± 61.87

147.75 ± 30.48

0.00

ALT (U/L)

63.06 ± 15.85a

55.82 ± 14.85a

124.43 ± 29.42b

99.06 ± 38.07b

0.00

Total cholesterol (mg/dL)

43.72 ± 7.98

46.68 ± 8.18

51.93 ± 2.93

52.86 ± 5.63

0.04

Triglycerides (mg/dL)

96.83 ± 24.25

94.49 ± 25.83

85.66 ± 31.82

68.84 ± 33.04

0.19

HDL cholesterol (mg/dL)

34.74 ± 11.13

34.19 ± 7.35

38.89 ± 4.24

38.37 ± 5.51

0.45

LDL cholesterol (mg/dL)

3.72 ± 2.64a

4.86 ± 0.84a,b

5.93 ± 0.71b

5.83 ± 1.40b

0.04

VLDL cholesterol (mg/dL)

17.82 ± 2.29

20.20 ± 3.62

19.58 ± 5.26

a

a

a,b

b

a,b

b

b

b

b

b

b

13.77 ± 6.61

a

0.05

Statistically significant differences were found as indicated (data were expressed as mean ± S.D., n = 10; ANOVA, posthoc
Bonferroni test, *P < 0.05; a,b, c: different letters on the same line indicate the difference between groups). Abbreviations: C,
control group; A, apitoxin treated group; D, diabetic group; DA, apitoxin treated diabetic group; AST, aspartate aminotransferase;
ALT, alanine aminotransferase; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; VLDL,
very low-density lipoprotein cholesterol.

The increase in diabetic oxidative stress caused TOS
levels to rise and TAS levels to decrease. The effect of
apitoxin is insignificant as statistical.
GSH reserve decreases due to elimination of oxidative
molecules [21]. The toxic effects of apitoxin on healthy cells
have been associated with an increase in ROS production
which is in agreement with the mechanisms reported by
others [17].
Due to the effect of STZ [26], plasma insulin
concentration in diabetic rats has decreased. An
insignificant increase in plasma insulin levels observed

in the DA group does not comply with apitoxin’s effect of
increasing insulin plasma concentration, as discussed in
previous studies [6,8].
The increase of ALT and AST observed in diabetic
rats treated with apitoxin may be a sign of hepatotoxicity.
Therefore, hepatic glycogen stores may have decreased,
and/or hepatic glyconeogenesis capacity may have
decreased. Perhaps this may be the reason for the decline
in FBG level, especially in the 1st and 2nd weeks, in the
DA group. To interpret this condition more clearly, it is
obvious that, in future studies, measurement of hepatic
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Table 2. Hematologic parameters measured in groups.
C
(n = 10)

A
(n = 10)

D
(n = 10)

DA
(n = 10)

P

42.33 ± 1.75

41.20 ± 2.14

40.15 ± 3.49

43.87 ± 1.81

0.07

RBC (x10 /L)

8.23 ± 0.17

8 ± 0.37

7.79 ± 0.12

8.10 ± 0.22

0.14

HGB (g/dL)

14.95 ± 0.76

14.37 ± 0.83

13.83 ± 1.15

14.88 ± 0.68

0.12

MCV (fL)

51.50 ± 1.39

52.65 ± 1.28

53.24 ± 1.49

54.23 ± 1.32

0.02

MCHC (g/dL)

35.27 ± 0.56

34.78 ± 0.29

34.42 ± 0.62

c

33.87 ± 0.54

0.00

WBC (x109/L)

6.78 ± 3.32a,b

5.12 ± 1.45a

8.95 ± 1.46b,c

11.17 ± 2.40c

0.00

LYM (x10 /L)

4.07 ± 1.62

3.15 ± 1.44

6.07 ± 1.84

5.98 ± 2.16

0.02

MON (x109/L)

0.48 ± 0.39

0.37 ± 0.56

0.33 ± 0.08

1.47 ± 1.41

0.06

GRAN (x10 /L)

2.40 ± 1.47

1.84 ± 0.98

2.55 ± 0.6

4.78 ± 1.27

0.00

LYM (%)

62.5 ± 14.57

61.78 ± 21.34

66.57 ± 9.89

54.1 ± 17.35

0.61

MON (%)

9.37 ± 5.12

2.95 ± 1.29

4.05 ± 1.17

8.12 ± 4.74

0.01

GRAN (%)

30.17 ± 9.58

33.22 ± 18.97

29.38 ± 8.89

37.78 ± 14.20

0.70

PLT (x10 /L)

589.17 ± 186.68

918.33 ± 118.96

116.83 ± 93.61

442 ± 188.75

0.00

MPV (fL)

5.80 ± 0.46a

5.58 ± 0.23a

6.48 ± 0.28b

6.70 ± 0.32b

0.00

PDW

16.43 ± 0.48

HCT (%)
12

a

9

9

9

a,b

a

a,b

a,b

a,b

b,c

a

a

b

a

a

a,b

b

a

b

b

b

b

b,c

c

16.13 ± 0.29

a

a,c

a

17.48 ± 0.55

c

b

16.87 ± 0.33

b

0.00

Statistically significant differences were found as indicated (data were expressed as mean ± S.D., n = 10; ANOVA, posthoc
Bonferroni test, *P < 0.05; a,b, c: different letters on the same line indicate the difference between groups). Abbreviations:
C, control group; A, apitoxin treated group; D, diabetic group; DA, apitoxin treated diabetic group; HCT, hematocrit;
RBC, red blood cells; HGB, hemoglobin; MCV, mean cell volume; MCHC, mean hemoglobin concentration per RBC;
WBC, white blood cells; LYM, lymphocytes; MON, monocytes; GRAN, granulocytes; PLT, platelets; MPV, mean platelet
volume; PDW, platelet distribution width.

glycogen stores and histopathological examination of the
liver is required.
Increased AST and ALT parameters due to experimental
DM have been reported previously [27]. This finding is
consistent with our research findings. Apitoxin causes
AST and ALT release from tissue and organ cells [19,28].
In this study, similar results were obtained as mentioned
in previous studies on AST, but the results do not match
in terms of ALT [16]. It is thought that this situation may
be caused by apitoxin-induced tissue and organ damage
and the combined effect of both apitoxin and experimental
diabetes. The increase in ALT level observed in diabetics
may be caused by hepatocellular damage similar to the
literature [19,29]. However, the fact that there was no
significant increase in ALT level suggests that apitoxin
alone did not cause liver damage. Besides, the collection
of blood samples was not divided by time intervals, but
only at the end of the study were AST and ALT parameters
examined. The method, frequency and dose of apitoxin
administration may have caused this condition.
In experimental STZ-induced DM, an increase in total
cholesterol (TC) levels has been reported in Wistar albino
rats [30]. As we observed in our study, an increase in TC
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levels was reported in experimental DM, which is due to an
increase in LDL. The TC levels of the diabetic rats injected
with apitoxin were increased. Considering that apitoxin
application has no effect on TC levels, it can be said that the
reason for the increase in TC levels is caused by diabetes.
The absence of changes in triglyceride and HDL cholesterol
levels in the experimental DM model is in agreement with a
previous study [31]. The increase of TC and LDL in the DA
group can be discussed by speculating on the findings. The
inability of apitoxin to fully normalize the levels of FBG,
insulin, and oxidants may be responsible for this situation.
DM-induced oxidative stress, as well as changes in FBG
and insulin levels, may have caused increases in WBC,
GRAN, and LYM numbers [32–34], and a decrease in PLT
count [35,36].
As expected, the food intake of diabetic animals in
group D increased, and bodyweight decreased. Apparently,
the saline injection did not adversely affect food intake. The
trend of decreasing bodyweight observed in the DA group
may indicate that apitoxin as a stressor reduced the appetite
of rats and hindered bodyweight gain.
It is known that water intake shows a circadian rhythm
parallel to food intake, which was observed in groups
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Figure 3. Bodyweight, food, and water intake changes during the study period. Bar graph A showing the means, in g and +S.D., of
bodyweight in-group comparison parameters measured weekly in study groups (ANOVA, post-hoc Bonferroni test, *P < 0.05,
comparison of weeks amongst themselves). Bar graph B showing the means, in g and +S.D., of food intake in-group comparison
parameters measured weekly in study groups, and bar graph C showing the means, in mL and +S.D., of water intake in-group comparison
parameters measured weekly in study groups (ANOVA, post-hoc Bonferroni test, *P < 0.05, compared with day 0; **P<0.05, compared
with 1st week; Ϯ P<0.05, compared with 2nd week; Ϯ Ϯ P<0.05, compared with 3rd week). C, control group; A, apitoxin treated group; D,
diabetic group; DA, apitoxin treated diabetic group. 0, first day of FBG measurement; 1, 2, 3, 4, weeks after STZ injection day.

C, A, and D [37]. However, lower water and food intake
observation in the DA group than in the D group may be
related to the FBG’s tendency to decrease in the DA group
especially in the 1st and 2nd weeks.
As stated in previous studies, aggression, hyperactivity,
and convulsions that we observed in our study are likely
caused by apitoxin [38]. Apparently, edema was observed
in the rats due to histamine, which was both introduced
into the injection medium as an apitoxin component,

and released by mast cells during an allergic reaction.
Breathing difficulties observed may have been due to
swelling observed around the nose and neck.
In the present study, the effects of apitoxin therapy
(which is becoming more widely-touted for use as
an antiinflammatory) were evaluated on the oxidantantioxidant status and some biochemical parameters in
rats with experimental DM. In our study, we observed
the negative effects of apitoxin on oxidative stress
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parameters in general, and positive effects on FBG. Results
reported herein should be considered in the light of some
limitations. The relationship between food intake and
plasma insulin concentration should be supported by an
oral glucose tolerance test. In the framework of the DMapitoxin relationship, we think that the pathophysiology
of changes in macroscopic and microscopic inflammation
findings, inflammation mediators, and biochemical and
hematological parameters in various tissues and organs,
especially the pancreas, should be measured and evaluated
at a molecular level. A study evaluating the histopathological
measurements of apitoxin in the pancreas [16] and liver
[39] in a similar experimental model by future researchers
would be useful in this regard. In addition, it is proposed
that the dose-response associations for various dosage-peradministration studies should be performed to illuminate
the apitoxin effect in vivo, and the samples should be taken
intermittently during the study and the results evaluated
at peracute, acute, subacute, and chronic levels. Also,

comparative analysis of a positive control agent known
to be antidiabetic with apitoxin [16] may be useful in
elucidating the mechanism of action of apitoxin, so that
the possible effects of apitoxin on diabetes can be discussed
less speculatively. In the current form of this research, the
available findings for the use of apitoxin as an antidiabetic
or as a regulator for diabetic complications are preliminary
and a full investigation of the aforementioned conditions
is envisaged in future studies.
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